

## GSK 呼吸道討論會

時間: 2025/05/10 (Sat.) 12:30-15:50

地點: W Hotel 11F 策略會議室 1



台灣呼吸健康促進協會  
Taiwan Respiratory Health Promotion Association

## Key Message Summary

### Prevention to Treatment:

### What We Can Do More for COPD Patient?

張博瑞 醫師 林口長庚

#### RSV:

- GOLD Vaccination Recommendation: Level A in > 60 y/o COPD Pt.
- Prevalence of COPD among adults with RSV:
  - Inpatient: 30.84%
  - Outpatient: 10.04%
- RSV-related mortality in COPD: ~10%
- **AREXVY® (欣剋融) 與其它 RSV 疫苗的差異為何?**
  - 疫苗成分與技術:
    - ◆ AREXVY® 為重組前融合蛋白( RSV PreF )疫苗, 搭配 GSK 的 AS01\_E 佐劑系統, 可增強免疫反應。
    - ◆ 佐劑的使用在年長者身上尤其重要, 可有效刺激較衰退的免疫系統。
  - 臨床試驗數據:
    - ◆ 在臨床試驗中, 顯示對 RSV A/B 皆有保護力, 可顯著降低年長者因 RSV 感染而導致的下呼吸道疾病、重症及住院機率。
  - 免疫持續性:
    - ◆ 初步數據顯示接種後於三年內仍有顯著免疫保護, 後續若需要追加劑, 亦需依官方建議或臨床實證更新。
- **AREXVY 欣剋融是唯一具有 3 年保護力及安全性數據的 RSV 疫苗**

#### COPD

- GOLD: 1 moderate exacerbation or EOS>100, favor to add on ICS.
- Trelegy 是 GOLD 指引中提到可以降低死亡率的藥物選擇之一。
- QD vs BID: 在晨間的肺功能差異很大。
- SITT Differentiation: 透過不同實驗, 能看出 Once-daily Trelegy 優於其他 Twice-daily SITT.

### Why Proactive Regular Regime is Important for Asthma Patient

劉景隆 醫師 台北馬偕

#### Asthma

- GINA recommend ICS-containing treatment, to control symptoms, and to reduce risk of severe exacerbations.
- Gap between patients and physicians on asthma management.
- Regular daily maintenance dosing of ICS provides sustained broncho protection (FF > FP ≥ BUD).
- Patients initiating FF/VI had better adherence and lower risk of discontinuing treatment versus B/F or FP/SAL.
- Track 2,

If Track 1 is not possible,  
If patient is stable with good adherence and no exacerbations.

**Anti-IL-5 when and how? Using biomarkers and clinical characteristics to target T2 inflammation**

潘奕宏 醫師 安泰醫院

**Severe Asthma:**

- Severe eosinophil asthma is an important phenotype in asthma, which can be targeted by anti-IL 5 / IL 5-R.
- Mepolizumab showed greater response to patient with higher blood eosinophils, adult onset, and patient with nasal polyposis.
- Not only eosinophil plays important role in severe asthma but also IL-5.
- Mepolizumab showed good evidence on epithelial barrier dysfunction, immune imbalance, mucus plugging and airway remodeling.